GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma

GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity

(2021) Sabine Heitzeneder et al.   CANCER CELL

Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma

(2021) Nicola Tumino et al.   Journal of Hematology & Oncology

Tuning the Antigen Density Requirement for CAR T-cell Activity

(2020) Robbie G. Majzner et al.   Cancer Discovery

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies

(2020) Jordan Gauthier et al.   BLOOD

Counteracting CAR T cell dysfunction

(2020) Mansour Poorebrahim et al.   ONCOGENE

Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma

(2020) Karin Straathof et al.   Science Translational Medicine

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

(2019) Sarwish Rafiq et al.   Nature Reviews Clinical Oncology

Chimeric Antigen Receptor Therapy

(2018) Carl H. June et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma

(2018) Concetta Quintarelli et al.   OncoImmunology

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

(2018) Ruth Ladenstein et al.   LANCET ONCOLOGY

CAR T Cell Therapy for Neuroblastoma

(2018) Rebecca M. Richards et al.   Frontiers in Immunology

Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials

(2017) Ruth Ladenstein et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting

(2017) Julie R. Park et al.   JOURNAL OF CLINICAL ONCOLOGY

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

(2017) Andras Heczey et al.   MOLECULAR THERAPY

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

(2017) Terry J Fry et al.   NATURE MEDICINE

Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma

(2017) Jeremy S. Abramson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer

(2017) Kristen M. Hege et al.   Journal for ImmunoTherapy of Cancer

123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel

(2016) V. Lewington et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Using cumulative sums of martingale residuals for model checking in nested case-control studies

(2015) Ørnulf Borgan et al.   BIOMETRICS

Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation

(2015) X. Zhou et al.   BLOOD

Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15

(2014) Y. Xu et al.   BLOOD

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

(2011) C. U. Louis et al.   BLOOD

Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

(2011) Antonio Di Stasi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

(2008) Martin A Pule et al.   NATURE MEDICINE